Physician profile
Hoangvy Le
NPI 1841619095
$4,158.68
in general payments reported to CMS, 2019-2025
26 companies · $1,906 in 2025
The $1,906 reported for 2025 was more than what 95% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $44.35 · 2020: $81.59 · 2021: $59.48 · 2022: $238 · 2023: $791 · 2024: $1,038 · 2025: $1,906.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,735.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,735.13 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $1,129.34 | 2023-2025 | Otezla, Repatha, Otezla |
| Bayer Healthcare Pharmaceuticals INC. | $378.36 | 2022-2025 | |
| Astrazeneca Pharmaceuticals LP | $343.47 | 2023-2025 | Farxiga, Airsupra, Lokelma |
| Gilead Sciences, INC. | $330.01 | 2023-2025 | |
| Abbvie INC. | $305.56 | 2020-2025 | |
| Aimmune Therapeutics, INC. | $257.11 | 2025 | Vowst, Zenpep |
| Lilly USA, LLC | $209.90 | 2022-2025 | Mounjaro, Zepbound, Jardiance |
| Agios Pharmaceuticals, INC. | $208.28 | 2024-2025 | Pyrukynd |
| Novo Nordisk INC | $191.39 | 2021-2025 | Ozempic, Rybelsus |
| Pfizer INC. | $134.89 | 2023-2025 | |
| Nestle Healthcare Nutrition INC. | $132.18 | 2022-2023 | |
| Glaxosmithkline, LLC. | $76.51 | 2023-2024 | Arexvy, Shingrix |
| Boehringer Ingelheim Pharmaceuticals, INC. | $75.07 | 2019-2024 | Jardiance |
| Kowa Pharmaceuticals America, INC. | $71.57 | 2025 | Zoryve |
| Madrigal Pharmaceuticals | $41.99 | 2025 | Rezdiffra |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $41.31 | 2024 | Tremfya |
| Amarin Pharma, INC. | $34.06 | 2020-2021 | |
| Seqirus USA INC | $33.65 | 2025 | Fluad, Flucelvax |
| Exact Sciences Corporation | $28.11 | 2025 | Cologuard Collection Kit |
| Novartis Pharmaceuticals Corporation | $26.48 | 2025 | |
| Scilex Pharmaceuticals INC. | $21.79 | 2025 | |
| Hologic Sales and Service, LLC | $21.45 | 2025 | Thinprep 2000 Processor, Aptima |
| Alk-Abello, INC | $21.00 | 2024 | Grastek, Ragwitek, Odactra |
| Horizon Therapeutics Plc | $16.57 | 2023 | Tepezza |
| Astellas Pharma US INC | $14.89 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $13.74 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Hoangvy Le listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.